Kairos Pharma, Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KAPA research report →
About the company
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma.
- CEO
- John S. Yu
- IPO
- 2024
- Employees
- 1
- HQ
- Los Angeles, CA, US
Price Chart
- Market Cap
- $7.92M
- P/E
- -1.24
- P/S
- 0.00
- P/B
- 1.46
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -92.26%
- ROIC
- -114.27%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,447,000 · -109.26%
- EPS
- $-0.30 · -30.43%
- Op Income
- $-5,572,000
- FCF YoY
- 13.00%
- 52W High
- $2.11
- 52W Low
- $0.33
- 50D MA
- $0.49
- 200D MA
- $0.74
- Beta
- 1.36
- Avg Volume
- 135.55K
Get TickerSpark's AI analysis on KAPA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 25 | Bhowmick Neil | other | 171,756 |
| Oct 8, 25 | Bae Hyun W. | other | 19,084 |
| Sep 16, 25 | Bae Hyun W. | other | 10,000 |
| Oct 8, 25 | Murali Ramachandran | other | 152,672 |
| Oct 8, 25 | Keyoung Hansoo Michael | other | 19,084 |
| Sep 16, 25 | Keyoung Hansoo Michael | other | 10,000 |
| Oct 8, 25 | Singhvi Rahul | other | 19,084 |
| Oct 8, 25 | Samuelson Doug | other | 152,672 |
| Oct 8, 25 | Yu John S | other | 190,840 |
| Dec 10, 24 | Singhvi Rahul | other | 0 |
Our KAPA coverage
Recent articles, reports, and earnings notes.
No research on KAPA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KAPA report →Similar companies
Peers in the same neighborhood.